Introduction to ARA-290
ARA-290 (also known as Cibinetide) is a synthetic 11-amino acid peptide derived from erythropoietin (EPO). Unlike full EPO, ARA-290 does not stimulate red blood cell production or affect hematocrit levels. Instead, it selectively activates the innate repair receptor (IRR), making it a specialized research tool for neuroprotection, chronic inflammation, and tissue repair studies.
ARA-290 is gaining traction in research focused on neuropathic pain, diabetic complications, sarcoidosis, and small fiber neuropathy.
How ARA-290 Works
ARA-290 binds to the innate repair receptor complex, triggering anti-inflammatory and reparative signaling pathways. It reduces pro-inflammatory cytokines, promotes tissue protection, and supports nerve regeneration without activating the EPO receptor responsible for erythropoiesis. This selective action allows researchers to study healing benefits while avoiding unwanted blood-related effects.
Key Research-Backed Benefits of ARA-290
Neuropathic Pain Relief
Multiple studies show significant reduction in pain scores for small fiber neuropathy and diabetic neuropathy models.
Anti-Inflammatory Effects
ARA-290 strongly suppresses chronic inflammation while supporting tissue repair.
Nerve Regeneration
ARA-290 promotes repair of damaged nerves and improves nerve conduction in preclinical and early clinical research.
Diabetic Complications Research
ARA-290 shows potential benefits for diabetic wound healing and metabolic nerve damage.
Sarcoidosis and Autoimmune Models
ARA-290 is studied for reducing symptoms and improving quality of life markers.
Cardioprotective Effects
Emerging data on protection against ischemia-reperfusion injury.
Low Systemic Impact
ARA-290 has no significant effect on hemoglobin or red blood cell count.
ARA-290 Research Dosage Protocols
Important: The following summaries are from published preclinical and clinical research for laboratory and in vitro use only.
-
Neuropathic Pain / Nerve Repair Studies: 1–4 mg per day subcutaneously, often divided into 2 administrations.
-
Chronic Inflammation Research: 2 mg daily or every other day for 4–12 weeks.
-
Exploratory Dosing: Clinical trials have safely used up to 4 mg daily for extended periods.
-
Administration: Subcutaneous injection. Reconstitute with bacteriostatic water (typical: 10 mg vial with 2 mL yields 5 mg/mL).
-
Cycle Structure: Common protocols run 4–8 weeks on, followed by evaluation. Some longer-term studies have used daily dosing for 12+ weeks with monitoring.
Reconstitution Note (Research Only): Use bacteriostatic water. Store reconstituted solution refrigerated and use within recommended stability period.
Why Researchers Choose ARA-290
ARA-290 fills a unique niche by offering potent tissue-protective and anti-inflammatory effects without the hematological risks of erythropoietin. It is especially valuable for studying difficult-to-treat neuropathic conditions and chronic inflammatory states.
Research-Grade ARA-290
Important Research Notice: ARA-290 is sold by Amino Fuel Labs strictly for laboratory research and in vitro use only. It is not FDA-approved for human consumption.
For scientists exploring neuroprotection, chronic pain, inflammation, or tissue repair pathways, we provide high-purity ARA-290 with independent testing and fast domestic shipping.
Explore More Research Peptides
Browse our full research peptide catalog including Retatrutide, Tesamorelin, BPC-157, TB-500, GHK-Cu, Semax, Selank, NMN, and more.
Have questions about ARA-290 research protocols or how it compares to other neuroprotective peptides? Leave a comment below — we're here to support the research community.
This article is for educational and research purposes only. ARA-290 is sold for research use only and is not intended for human consumption.
